Clinical Trials Browser

Maximum Tolerated Dose × Plasma cell × 30 days × Clear all

NCT05976555 2026-05-20

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Phase 1 Not yet recruiting

Multiple Myeloma